Stem Cells To Cure Sickle Cell Anemia
DOI:
https://doi.org/10.65539/056mjw33Keywords:
sickle cell anemia, stem cell transplantation, HSCT, gene therapy, genome editingAbstract
Sickle cell anemia (SCA) is one of the most prevalent genetic disorders in the world and the most common congenital anemia in the United States. The severity of SCA spans from mild clinical cases, managed by careful living, to severe cases involving bone crises, infection, stroke, and multi-organ failure. Hematopoietic stem cell transplantation (HSCT) is the most widely known and effective method to cure the disease and is used today in only severe cases due to risks of graft rejection and fatal infections. The use of stem cells for the cure of sickle cell disease from the early days of transplantation to the most recent breakthroughs in stem cell therapy, gene therapy and genome-editing will be examined in this review.
Downloads
References
Savitt, T. L., & Goldberg, M. F. (1989). Herrick's 1910 Case Report of Sickle Cell Anemia: The Rest of the Story. Journal of the American Medical Association, 261(2), 266-271. https://doi.org/10.1001/jama.1989.03420020120042.
Haldane JBS. Disease and evolution. Ric Sci. 1949;19:68–76.
Allison, A. C. Ann NY Acad Sci. 91 710–729(1961).
Deisseroth A, N. A. (1978). Chromosomal localization of human beta globin gene on human chromosome 11 in somatic cell hybrids. Proc Natl Acad Sci U S A. , 75 (3), 1456-60.
Colah RB et al. (2015). Sickle cell disease in tribal populations in India. Indian J Med Res , 141 (5), 509-515.
Serjeant, G. (2013). The natural history of sickle cell disease. Cold Spring Harb Perspect , 3 (10).
Grosse SD, O. I. (2011). Sickle Cell Disease in Africa: A Neglected Cause of Early Childhood Mortality. Am J Prev Med , 41 (S4).
Platt OS, B. D. (1994). Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med , 330 (23), 1639-44.
Sunhil, J. (2015, Oct). Disparities in Sickle Cell Disease Management: Quest for Global Protective Immunity". MOJ Cell Sci & Rep .
Kauf TL, C. T.-P. (2009). The cost of health care for children and adults with sickle cell disease. Amer J Hem , 84 (6), 323-7.
Weismann IL, S. J. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capacity to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood , 112, 3543-53.
Thomas ED, L. H. (1957). Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med , 491-6.
Walter MC, P. M. (1996). Bone marrow transplantation for sickle cell disease. N Engl J Med , 335 (6), 369-76.
Bhatia M, S. S. (2015). Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med , 229-38.
Bonlanos-Meade J, B. R. (2009). Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol , 21 (2), 158-61.
Krishnamurti L, A. S. (2003). Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. . Bone Marrow Trans , 31, 547-50.
Saraf SL, O. A.-L. (2018). Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease. Bio Blood Mar Trans .
Jinek, M., et al. (2012) Science, 337, 816–821.
Denver, D.P., et al. ( 2016) Nature 539, 384-389.
Kanter J, W. M. (2018). Interum results from a phase 1/2 clinical study of Lentiglobin gene therapy for severe sickle cell disease. Blood.
Malik P, G. M. (2018). Gene therapy for sickle cell anemia using a modified gamma globin lentivirus vector and reduced intensity conditioning transplant shows promising correction of the disease phenotype. American Society of Hematology Annual Meeting. San Diego: Blood.
Bunn HF (1999). Induction of fetal hemoglobin in Sickle Cell Disease. Blood, 93:1787-1789.
Sankaran VG, M. T. (2008). Human fetal hemoglobin expression is regulated by developmental stage-specific repressor BCL11A. Science , 1839-42.
Brendel et al. (2016) Lineage-specific BCL11A knock-down circumvents toxicities and reverses sickle phenotype. J Clin. Invest., 126(10): 3868-3878.
Kolata G (2019). These patients had sickle-cell disease. Experimental therapies might have cured them. New York Times.
Published
Issue
Section
License
Copyright (c) 2020 Tolulope O. Rosanwo (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
